Suppr超能文献

CD28发出一种独特信号,导致RelA和p52核因子-κB亚基选择性募集至白细胞介素-8和Bcl-xL基因启动子上。

CD28 delivers a unique signal leading to the selective recruitment of RelA and p52 NF-kappaB subunits on IL-8 and Bcl-xL gene promoters.

作者信息

Marinari Barbara, Costanzo Antonio, Marzano Valeria, Piccolella Enza, Tuosto Loretta

机构信息

Department of Cellular and Developmental Biology, University of Rome La Sapienza, 00185 Rome, Italy.

出版信息

Proc Natl Acad Sci U S A. 2004 Apr 20;101(16):6098-103. doi: 10.1073/pnas.0308688101. Epub 2004 Apr 12.

Abstract

CD28 is one of the most important costimulatory receptors necessary for full T lymphocyte activation. The CD28 receptor can enhance T cell antigen receptor (TCR) signals, as well as deliver independent signals. Indeed, CD28 engagement by B7 can generate TCR-independent signals leading to IkappaB kinase and NF-kappaB activation. Here we demonstrate that the TCR-independent CD28 signal leads to the selective transcription of survival (Bcl-xL) and inflammatory (IL-8 and B cell activation factor, but not proliferative (IL-2), genes, in a NF-kappaB-dependent manner. CD28-stimulated T cells actively secrete IL-8, and Bcl-xL up-regulation protects T cells from radiation-induced apoptosis. The transcription of CD28-induced genes is mediated by the specific recruitment of RelA and p52 NF-kappaB subunits to target promoters. In contrast, p50 and c-Rel, which preferentially bind NF-kappaB sites on the IL-2 gene promoter after anti-CD3 stimulation, are not involved. Thus, we identify CD28 as a key regulator of genes important for both survival and inflammation.

摘要

CD28是完全激活T淋巴细胞所必需的最重要的共刺激受体之一。CD28受体可增强T细胞抗原受体(TCR)信号,并传递独立信号。事实上,B7与CD28结合可产生不依赖TCR的信号,导致IκB激酶和NF-κB激活。在此我们证明,不依赖TCR的CD28信号以NF-κB依赖的方式导致存活基因(Bcl-xL)和炎症基因(IL-8和B细胞活化因子,但不包括增殖基因(IL-2))的选择性转录。CD28刺激的T细胞可主动分泌IL-8,Bcl-xL的上调可保护T细胞免受辐射诱导的凋亡。CD28诱导基因的转录是通过RelA和p52 NF-κB亚基特异性募集到靶启动子来介导的。相反,抗CD3刺激后优先结合IL-2基因启动子上NF-κB位点的p50和c-Rel则不参与此过程。因此,我们确定CD28是对存活和炎症都很重要的基因的关键调节因子。

相似文献

引用本文的文献

7
Regulation of T Helper Cell Fate by TCR Signal Strength.T 辅助细胞命运的 TCR 信号强度调节。
Front Immunol. 2020 May 19;11:624. doi: 10.3389/fimmu.2020.00624. eCollection 2020.

本文引用的文献

2
Antibody therapy for rheumatoid arthritis.类风湿关节炎的抗体疗法。
Curr Opin Pharmacol. 2003 Jun;3(3):323-8. doi: 10.1016/s1471-4892(03)00032-8.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验